IRVING, Texas, February 26, 2026
Caris Life Sciences® (NASDAQ: CAI) announced an interim readout from its Achieve 1 clinical study, demonstrating strong performance of Caris Detect™, a multi-cancer early detection (MCED) blood test powered by Whole Genome Sequencing (WGS) and artificial intelligence (AI). The interim analysis highlights high sensitivity across cancer stages and 99.1% specificity in asymptomatic individuals, supporting the company’s strategy to move beyond methylation-only approaches toward comprehensive genomic interrogation. The findings mark a significant milestone in Caris’ mission to enable earlier cancer detection when treatment outcomes are most favorable.
Robust Sensitivity Across Early and Advanced Stages
The Achieve 1 study evaluated 2,122 total samples, including 1,505 undiagnosed individuals and 617 confirmed cancer cases spanning stages I–IV. Interim data demonstrate 56.8% sensitivity in Stage I cancers, increasing to 70.1% in Stage II, 77.1% in Stage III, and 99.1% in Stage IV, reflecting progressive signal detectability as tumor burden increases. Importantly, combined Stage I–II sensitivity reached 61.3%, a key benchmark for early detection platforms aiming to identify malignancies before symptomatic progression.
Cancer-specific early-stage detection rates showed particularly strong signals in prostate (78.9%), lung (86.7%), uterus (73.7%), pancreatic (71.4%), and head and neck cancers (100%), though sample sizes varied. These data suggest that ultra-deep Whole Genome Sequencing can capture diverse molecular aberrations across multiple tumor types, including driver mutations, aneuploidy, transcriptomic changes, and epigenomic alterations.
High Specificity Critical for Screening Utility
Advertisement
Equally significant is the test’s specificity profile. In the 121-subject asymptomatic screening population with one-year follow-up confirming no cancer diagnosis, Caris Detect achieved 99.1% specificity, while specificity in the broader undiagnosed population reached 95.3%. High specificity is essential for MCED screening applications to minimize false positives and reduce unnecessary diagnostic procedures. Approximately 7% of undiagnosed subjects with follow-up were later diagnosed with cancer, indicating the study cohort was enriched for higher-risk individuals, potentially strengthening early signal detection analysis.
The Achieve 1 design incorporated a cross-validation methodology, with approximately 865 samples reserved for blinded validation, results of which are expected later in the first quarter of 2026. These forthcoming data will be pivotal in confirming reproducibility and informing commercialization and regulatory pathways.
Whole Genome Sequencing as a Differentiator
Caris attributes its performance advantage to the use of extreme ultra-deep Whole Genome Sequencing, rather than relying solely on methylation signatures. The company’s molecular profiling platform has processed over one million cases and generated more than 50 billion molecular markers, providing a substantial dataset for AI model training and refinement. By integrating comprehensive genomic data with advanced analytics, Caris aims to improve resolution in identifying subtle biological signals associated with early-stage malignancies.
Development of the next-generation Caris Detect platform is already underway, with planned incorporation of Whole Transcriptome Sequencing to further enhance detection performance. As the MCED field intensifies, differentiation based on sensitivity in early-stage cancers and high specificity in asymptomatic populations will likely determine competitive positioning and payer adoption.
If validated in larger populations, Caris Detect could complement existing screening modalities and expand precision oncology tools through minimally invasive blood-based testing. As sequencing costs decline and AI-driven analytics mature, integrated genomic platforms may play a central role in reshaping population-level cancer screening strategies.
Source: Caris Life Sciences press release
